Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO
I'm LongbridgeAI, I can summarize articles.Aspen Neuroscience, Inc. is offering 9,375,000 shares of common stock in its initial public offering at $15.00 per share, for gross proceeds of approximately $140.6 million. The company’s shares are approved to list on the Nasdaq Global Select Market under the symbol ASPE. Aspen plans to use the proceeds primarily to advance its Parkinson’s disease cell therapy candidate through clinical development, including a planned Phase 3 trial.
Business Description
Aspen Neuroscience develops therapies made from a patient’s own induced-pluripotent stem cells, which are reprogrammed from adult cells and then differentiated into specialized cells. Its lead candidate, sasineprocel, is a one-time cell therapy being studied for Parkinson’s disease. The treatment is designed to replace lost dopamine-producing neurons and is delivered to the brain through stereotactic surgery. In an ongoing open-label Phase 1/2a trial, 15 patients had been treated as of August 18, 2026; the company reported preliminary safety observations and improvements across several measures, while noting that the study has no control group and the results are not yet conclusive.
Aspen’s platform also supports a preclinical program developing gene-corrected microglia cells for pediatric leukodystrophies. The company manufactures its clinical candidate in San Diego and is developing automated processes using third-party platforms, with the goal of supporting production for later-stage trials and potential commercialization. Its approach is intended to avoid the long-term immunosuppression often required for donor-derived cell therapies, but the company faces clinical, regulatory, manufacturing, financing, and commercialization risks.
Market Overview
- Total addressable market: The prospectus estimates that about 300,000 U.S. patients with Parkinson’s disease are refractory to dopamine replacement therapy, with approximately half potentially eligible for cell replacement surgery; it does not provide a market-value estimate.
- Market growth: Parkinson’s disease prevalence has doubled globally over the past 25 years; the prospectus projects 25.2 million people worldwide will be living with the disease by 2050, a 112% increase from 2021.
- Market position: Aspen is a clinical-stage developer of autologous induced-pluripotent stem cell therapies, with sasineprocel in Phase 1/2a testing for Parkinson’s disease.
- Key competitors: Parkinson’s disease competitors include BlueRock Therapeutics/Bayer, Sumitomo, Hope Bio, Oryon, Kenai Therapeutics, and gene therapy developers such as AskBio/Bayer and MeiraGTx.
- Industry trends: Cell replacement approaches seek to restore dopamine-producing neurons; autologous therapies may avoid long-term immunosuppression, while automated manufacturing aims to improve consistency and scale.
Operational Metrics
- Clinical trial: 15 patients had received sasineprocel in the Phase 1/2a ASPIRO trial as of August 18, 2026; seven received a low dose and eight a high dose.
- Clinical follow-up: All 12 patients in the first three trial cohorts had at least one follow-up evaluation six months or later as of the data cutoff.
- Manufacturing capacity: The company is designing a modular automated process intended to support production for hundreds of patients annually per module.
- Manufacturing timelines: The three production stages take approximately three weeks, eight weeks, and five weeks, respectively, with quality-control testing typically requiring an additional four to five weeks.
- Employees: Aspen had 120 full-time employees and three part-time employees as of June 30, 2026.
- Geographic presence: The company is headquartered and operates its clinical manufacturing facility in San Diego, California; its initial commercial focus is North America.
- Partnerships and licenses: Key third parties include Cell X Technologies, Mytos Bio, ClearPoint Neuro, iPS Academia Japan, Sumitomo Pharma/RACTHERA, The Cleveland Clinic Foundation, and the Scripps Research Institute.
- Pipeline: Sasineprocel is in Phase 1/2a development for Parkinson’s disease; the microglia program remains preclinical, with IND-enabling studies expected to begin in the second half of 2027.
Financials Highlights
- Revenue (current): No product revenue to date; the company reported no revenue for the six months ended June 30, 2026.
- Revenue growth: Not applicable; Aspen has not generated product revenue.
- Operating income: Operating loss of $38.2 million for the six months ended June 30, 2026.
- Net income: Net loss of $36.5 million for the six months ended June 30, 2026.
Management
- Damien McDevitt, President, Chief Executive Officer and Director - Previously led Akcea Therapeutics as CEO and held leadership roles at Ionis Pharmaceuticals, Acadia Pharmaceuticals, and GlaxoSmithKline.
- Faheem Hasnain, Executive Chairman - Co-founder, chairman, and CEO of Gossamer Bio; previously led Receptos before its acquisition by Celgene and held senior roles at other biotechnology companies.
- Dalen Meeter, Chief Financial Officer - Previously served as CFO of Singular Genomics and held finance leadership roles at Illumina; began his career at KPMG.
- Lisa Johnson-Pratt, Sasineprocel Development Lead and Chief Commercial Officer - Has held leadership roles in clinical development, medical affairs, and commercialization at Aspen, Ionis, Akcea, GSK, and Merck.
- Kim Raineri, Chief Technology Officer - Previously held manufacturing and operations leadership roles at Tectonic Therapeutic, Nikon CeLL innovation, Lonza, and CryoLife.
IPO Structure
- Issuer: Aspen Neuroscience, Inc.
- Filing date: October 30, 2026
- Proposed ticker: ASPE
- Exchange: Nasdaq Global Select Market
- Price range: $15.00 per share
- Offering size: 9,375,000 shares at $15.00 per share; $140,625,000 in gross proceeds
- Shares offered: 9,375,000 shares, plus an underwriters’ option to purchase up to 1,406,250 additional shares
- Lead underwriters: Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co.
- Use of proceeds: Approximately $8.0 million for the Phase 1/2a ASPIRO trial, $110.0 million for a planned Phase 3 trial, $4.0 million for microglia programs, and the remainder for working capital and general corporate purposes.
Original SEC Filing: Aspen Neuroscience, Inc. - 424B4 - Oct. 30, 2026
